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Abstract
Introduction: Fibromyalgia (FM) is a prevalent disorder. However, few studies have evaluated the effect of treatment
interventions on biomarker expression. The aim of this review was to explore the efficacy of non-pharmacological
interventions on inflammatory biomarker expression, specifically cytokines, neuropeptides and C-reactive protein (CRP),
in FM patients.
Method: A literature search using PubMed, EMBASE, PsycINFO and the Cochrane library was performed from January
1990 to March 2015. Randomized controlled trials (RCTs) and non-RCTs published in English, French or Spanish
were eligible.
Results: Twelve articles with a total of 536 participants were included. After exercise, multidisciplinary, or dietary
interventions in FM patients, interleukin (IL) expression appeared reduced, specifically serum IL-8 and IL-6 (spontaneous,
lipopolysaccharide (LPS)-induced, or serum). Furthermore, the changes to insulin-like growth factor 1 (IGF-1) levels
might indicate a beneficial role for fatigue in obese FM patients. In contrast, evidence of changes in neuropeptide
and CRP levels seemed inconsistent.
Conclusion: Despite minimal evidence, our findings indicate that exercise interventions might act as an
anti-inflammatory treatment in FM patients and ameliorate inflammatory status, especially for pro-inflammatory
cytokines. Additional RCTs focused on the changes to inflammatory biomarker expression after non-pharmacological
interventions in FM patients are needed.
Introduction
Fibromyalgia (FM) is a prevalent disorder that affects to
2–8 % of the population [1–3], and it is characterized by
widespread pain, fatigue, memory problems and sleep
disturbances. Currently, it is one of the most common
disorders seen by primary care physicians [4] and the
second most common rheumatic disorder after osteo-
arthritis [5].
There are many possible treatments for FM that can be
classified as pharmacological and non-pharmacological,
and the latter can also be subclassified into psychological
and non-psychological interventions [6–12]. The efficacy
of these treatments is considered low to moderate, and
there are no significant differences between them when
administered in primary care or specialized settings [13].
The main criteria assessed in pharmacological and non-
pharmacological trials are function, quality of life, pain,
depression, anxiety and fatigue. All of these are subjective
symptoms assessed by questionnaire and are rated by the
patient or the clinician. However, few trials on FM include
biological outcomes, in particular an assessment of in-
flammatory biomarkers, despite neurogenic neuroinflam-
mation having been associated with the pathogenesis
of FM [14]. As mentioned, non-pharmacological treat-
ments are systematically recommended as an adjunctive
treatment for FM [10]; therefore our aim was to deter-
mine the efficacy of non-pharmacological interventions
* Correspondence: jgarcamp@gmail.com
3The Primary Care Prevention and Health Promotion Research Network
(REDIAPP), Barcelona, Spain
4Department of Psychiatry, Miguel Servet University Hospital, University of
Zaragoza, Avda Isabel La Católica I., 50009 Zaragoza, Spain
Full list of author information is available at the end of the article
© 2015 Sanada et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sanada et al. Arthritis Research & Therapy  (2015) 17:272 
DOI 10.1186/s13075-015-0789-9
on inflammatory biomarkers in FM patients, specifically
cytokines, neuropeptides, and C-reactive protein (CRP).
Methods
This systematic review followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guide-
lines (PRISMA) [15].
Search strategy and data extraction
A comprehensive computerized literature search of
PubMed, EMBASE, PsycINFO and the Cochrane library
was performed from January 1990 to March 2015 by an
expert in this field (MSV). The starting date was estab-
lished because the American College of Rheumatology
(ACR) criteria for the classification, with the definition
of FM, were published in 1990 [16]. For example, the
following search terms for the PubMed database were
used: (“fibromyalgia” [MeSH Terms] OR “fibromyalgia”
[All Fields] OR “Fatigue Syndrome, Chronic” [Mesh])
AND (“Cytokines” [Mesh] OR “Interleukins” [Mesh] OR
“Biological Markers” [Mesh] OR “Neuropeptides” [Mesh]
OR “C-Reactive Protein” [Mesh] OR biomarker* OR
cytokine* OR interleukin* OR neuropeptide* OR “C-
reactive protein” OR CRP).
The reference lists of the identified original articles
and reviews were also searched manually for additional
studies. The literature search was conducted independ-
ently by two authors (KS and MCPY). Any disagree-
ments were resolved by discussion and consensus, and
when in doubt, the final decision was made in consult-
ation with a third author (JGC). The last search was
conducted on 13 March 2015.
Eligibility criteria
The study eligibility criteria are shown in Table 1. We
excluded studies from the following cases: the first trial
was conducted in patients not only with FM but also
with chronic fatigue syndrome (CFS) (e.g., Light et al.
[17]); the second excluded trial used biomarkers as pre-
dictors or related factors to symptom severity (e.g., Ross
et al. [18]); the third assessed a mixed type treatment
plan with pharmacological and non-pharmacological
intervention [19]; the fourth conducted exercise tests
[20–22]; the fifth was written in German [23]; and the
sixth was published as a letter [24].
Assessment of study quality
The risk-of-bias tool is generally fitted to randomized
controlled trials (RCTs), but we can apply it to non-
RCTs, and a specific tool for this use is under develop-
ment [25]. In this systematic review, the risk of bias in
the included studies was assessed using the Cochrane
risk-of-bias tool [25].
Results
After the initial search of 535 records, 64 were found to
be duplicates (Fig. 1). We screened the titles and ab-
stracts, and 15 articles were assessed as full text. We fi-
nally included 12 articles with a total of 536 participants.
Characteristics of included studies
Of all of the included articles, two studies [26, 27] were
conducted with almost the same population. With regard
to interventions, three types were assessed: complemen-
tary and alternative medicine (CAM) (e.g., balneotherapy,
massage, mud bath, guided imagery, dance/movement
therapy, and dietary therapy), exercise, and multidisciplin-
ary therapy. All of the FM patients were diagnosed by the
1990 ACR criteria [16] (Ortega et al. [28] did not declare
the year of the ACR criteria), and the mean age of the par-
ticipants ranged from 43.4 to 57.0 years old (Ortega et al.
[28, 29] did not declare age). With respect to study design,
we included eight RCTs, and the remaining four articles
included were non-RCTs. According to the Cochrane
Table 1 Study eligibility criteria
Inclusion criteria Exclusion criteria
Participants Fibromyalgia patients (FM) or FM and a healthy population Patients with other diseases, mixed types of
patients (i.e., FM patients with other disorders), only
a healthy populationNo restrictions on the number of participants and the
diagnostic procedures were applied
Biomarkers Cytokines, neuropeptides and CRP Other biomarkers
Interventions Non-pharmacological interventions were eligible Mixed or blended non-pharmacological
interventions, only pharmacological interventions
Outcome At least one biomarker (cytokine or neuropeptide or CRP) outcome Studies in which biomarkers were used as
predictors to identify the participants were excluded
Study design RCTs, Non-RCTs
Publications Published in English, French or Spanish and as full-text
articles in peer-reviewed scientific journals from
January 1990 to March 2015
Published in other languages and as reviews,
case reports or letters
CRP C-reactive protein, Non-RCTs non-randomized controlled trials, RCTs randomized controlled trials
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risk-of-bias tool [25], two studies [30, 31] were consid-
ered high quality, but the other trials were low quality
with a high risk of bias (Figs. 2 and 3). In addition,
of our included trials, only four trials [26, 27, 32, 33]
were performed under active control conditions, al-
though two trials [26, 27] were almost the same
population. None of these studies included evidence
about how the participants rated both the primary
and active control conditions as credible, and the
likelihood of producing positive results due to base-
line intervention expectations was not evaluated.
Meanwhile, in relation to the baseline values of each
biomarker, our findings revealed that the baseline
levels of IL-8 and CRP in FM patients are signifi-
cantly increased when compared to the healthy
control group [28, 34].
Fig. 1 Algorithm for study selection (following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, Shamseer et al., [15])
Fig. 2 Risk-of-bias graph: reviews the authors’ judgments about each risk-of-bias item presented as percentages across all of the included studies
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Cytokines
We included nine articles with a total of 440 partici-
pants. The characteristics of each study are shown in
Table 2. Of all of the studies, 10 of the biomarkers exam-
ined were classified as pro-inflammatory cytokines, 4
were classified as anti-inflammatory cytokines, 5 were
classified as growth factors and 3 were classified as che-
mokines. Of the pro-inflammatory cytokines, IL-6 and IL-
8 were the most frequently measured in five studies each
([26, 28–31], [26, 28, 31, 34, 35], respectively), and IL-1β
and TNF-α were second in three studies each [28, 29, 31].
Of the anti-inflammatory cytokines, IL-10 was measured
in three studies [28, 29, 31]. For growth factors, insulin-
like growth factor-1 (IGF-1), IGF binding protein-3
(IGFBP3), and nerve growth factor (NGF) were measured
in two studies each [26, 27]. Of the chemokines, IL-8 was
assessed in five studies [26, 28, 31, 34, 35].
In terms of pro-inflammatory cytokines, three trials
[28, 34, 35] observed that the serum levels of IL-8 in FM
patients decreased within group between pre-intervention
and 4 months post pool-aquatic exercise (p <0.001) [28]
and 6 months post multidisciplinary therapy (p <0.05)
[34], and among groups 8 months post pool-aquatic exer-
cise (p <0.05) [35]. For IL-6, one trial [29] showed that the
spontaneous and lipopolysaccharide (LPS)-induced pro-
duction of IL-6 in FM patients decreased within group be-
tween pre-intervention and 8 months post pool-aquatic
exercise (p <0.001), although IL-6 levels increased within
group between pre-intervention and 4 months exercise (p
<0.001). In addition, Senna et al. [30] reported that the
levels of serum IL-6 in the dietary therapy group de-
creased within group between baseline and post 6 months
of intervention.
With regard to anti-inflammatory cytokines, the find-
ings were inconsistent. Ortega et al. [29] demonstrated
that the spontaneous production of IL-10 in FM patients
decreased within group between pre-intervention and 8
months post pool-aquatic exercise (p <0.001), whereas
LPS induced IL-10 to increase (p <0.05) within group.
With respect to growth factors, Bjersing et al. [27]
showed that the levels of total serum IGF-1 in lean FM
patients increased within group after 15 weeks of Nordic
walking (p <0.05).
Neuropeptides
We included five articles with a total of 193 participants.
Of these articles, two studies [26, 27] were also in-
cluded in the group that utilized cytokines and were
conducted with almost the same population. The
characteristics of each study are shown in Table 3. Of
all of the studies, nine of the biomarkers examined
were neuropeptides. Neuropeptide Y (NPY) was mea-
sured in three studies [26, 27, 36], and the others
were assessed in one study each.
For NPY, two trials [27, 36] demonstrated no consistent
findings. Bjersing et al. [27] demonstrated that the levels
of serum NPY in obese FM patients significantly increased
within group after 30 weeks (including 15-week exercise
and 15-week follow up) (p <0.05). By contrast, Bojner-
Horwitz et al. [36] reported that the levels of serum NPY
in both the dance/movement group and the control group
increased compared to baseline and month 14 of the study
within each group.
In terms of other neuropeptides, the concentrations of
urinary corticotropin releasing factor-like immunoreac-
tivity (CRF-L1) in the massage group decreased within
group after 6 weeks of massage treatment (p = 0.01) and
Fig. 3 Risk-of-bias summary: review of the authors’ judgments about
each risk-of-bias item for each included study
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Table 2 Characteristics of included trials related to cytokines
Reference Participants Study
design
Diagnosis
of FM
Treatment group Control group Study
duration
Outcomes Findings
Ardiç et al.
(2007) [37]
N = 31 RCT ACR 1990 Balneotherapy Usual care N/A IL-1α, CRP, PGE2,
LTB4, RF, ESR
In the balneotherapy group, the levels
of serum IL-1α significantly decreased
after intervention therapy (p <0.05)
Mean age: (n = 12) (n = 9) Two time points
43.5 ± 10.2 years
(balneotherapy)
3 weeks 3 weeks (before and at the
end of therapy)
48.8 ± 8.8 years
(usual care)
5 days per week Healthy Serum
43.4 ± 8.2 years (healthy) 20 minutes each (n = 10)
Gender:
female only
Ortega et al.
(2009) [28]
N = 27 Non-RCT
(pilot)
ACR Patients Healthy N/A IL-1β, IL-2, IFN-γ,
TNF-α, IL-8, IL-6, IL-4,
After 4 months of exercise, the levels
of circulating serum IL-8 and IFN-γ in
FM patients decreased significantly
(p <0.001, p <0.05, respectively)Age range: (unspecified
year)
(n = 14) (n = 13) IL-10, CRP, NA, cortisol
30–60 years (patients) Pool-aquatic exercise 2 time points
28–55 years (healthy) 4 months (before and two days after
finishing the exercise)
Gender: 3 days per week
female only 60 minutes each serum
Wang et al.
(2009) [34]
N = 100 Non-RCT ACR 1990 Patients (inpatients) Healthy 6 months IL-8 At the beginning of the study, the levels
of serum IL-8 in FM patients were
significantly higher than the healthy
control group (p <0.001)
Mean age: (n = 20) (n = 80) 4 time points
49.9 ± 6.8 years (patients) Multidisciplinary therapy (the beginning of the
study, 10 days after
At the end of the study (6 months),
the levels of serum IL-8 in FM patients
decreased significantly compared to
the beginning of the study (p <0.05)
with a decline to the normal range
48.4 ± 11.1 years (healthy) 3 weeks treatment, at resignation
(21 days), and at 6
Gender: 5 days per week months follow up)
male 15 %, female
85 % (patients)
8-hour session each serum
male 45.2 %, female 54.8 %
(healthy)
Bjersing et al.
(2012) [26]
N = 49 RCT ACR 1990 Nordic walking Active control:
Low-intensity
walking
30 weeks IL-6, IL-8, IGF-1,
IGFBP-3, NGF,
There were no significant differences
pre- and 15-week post-intervention in
the levels of serum IGF-1 and IGFBP-3
between the intervention and
active control groupMean age: (n = 26) (n = 23) SP, NPY, MMP-3
52 years (total) 15 weeks 15 weeks 3 time points: serum
IGF-1, IGFBP-3
The change in serum free IGF-1
correlated positively with an
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Table 2 Characteristics of included trials related to cytokines (Continued)
alteration in CSF SP levels (p <0.1), NPY
(p = 0.001) and pain threshold (p <0.1)
Gender: twice a week twice a week (baseline, after 15
weeks of exercise, 30
female only 40–45 minutes each 40–45 minutes
each
weeks of follow up)
Two time points:
CSF IL-6, IL-8, NGF, SP,
NPY, MMP-3
(baseline and after 15 weeks
of exercise)
serum, CSF
Ortega et al.
(2012) [29]
N = 18 Non-RCT ACR 1990 Patients Healthy N/A IL-1β, TNF-α, IL-6,
IL-10, CRP
After 4 months of exercise, the spontaneous
and LPS-induced production of IL-6 in FM
patients increased and spontaneous TNF-α
decreased compared to their basal stateAge range: (n = 9) (n = 9) 3 time points
30–60 years (patients) Pool-aquatic exercise (before, midway
through: 4 months and
28–55 years (healthy) 8 months at the end of
program: 8 months)
After 8 months of exercise, the production
of IL-1β, TNF-α, IL-6 in FM patients decreased
compared to their basal state (both
spontaneously and in response to LPS
activation), with levels similar to
(and even lower than in the case
of the spontaneous release
of TNF-α) those in the
healthy control group
Gender: twice a week (samples were
collected 2 days after
female only 60 minutes each finishing the last session
of the exercise)
serum
After 8 months of exercise, the spontaneous
production of IL-10 decreased and the
LPS-induced production of IL-10 increased
compared to their basal state, with levels
higher than those in the healthy
control group
Senna et al.
(2012) [30]
N = 83 RCT ACR 1990 Dietary weight loss Usual care N/A IL-6, CRP The levels of serum IL-6 in the intervention
group were significantly lower than the
usual care group after 6 months of
intervention (p <0.05), although there
were no significant differences
between the two groups at baseline.
Mean age: (n = 41) (n = 42) two time points
44.8 ± 13.6 years
(intervention)
6 months 6 months (baseline and after
6 months of
intervention)
(BMI 32.3 ± 1.4) 1200 kcal/day serum
46.3 ± 14.4 years
(usual care)
(with 15–20 % of energy
intake in the form of
protein, 50–55 % in the
form of carbo-hydrates,
and approximately 30 %
in the form of fat divided
across three meals)
(BMI 32.8 ± 1.4)
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Table 2 Characteristics of included trials related to cytokines (Continued)
Gender:
male 9.8 %, female
90.2 % (intervention)
male 9.5 %, female
90.5 % (usual care)
Bjersing et al.
(2013) [27]
N = 48 RCT ACR 1990 Nordic walking Active control:
low-intensity
walking
30 weeks IGF-1, IGFBP3, NGF,
adiponectin, leptin,
resistin, NPY
In lean patients, the levels of total
serum IGF-1 increased after 15
weeks of exercise (p <0.05).
Mean age: (n = 26) (n = 22)
52.0 years (lean group) (lean 4, overweight
15, obese 7)
(lean 5,
overweight 11,
obese 6)
3 time points The change in the levels of total serum
IGF-1 differed significantly between
lean and obese patients (p = 0.01).
(BMI 18.5 to 24.9, n = 9) 15 weeks 15 weeks (baseline, after 15 weeks
of exercise, 30
53.0 years (overweight
group)
twice a week twice a week weeks of follow up)
(BMI 25 to 29.9,
n = 26)
40–45 minutes each 40–45 minutes
each
serum, CSF
51.0 years
(obese group)
(BMI ≥30, n = 13)
Gender:
female only
Bote et al.
(2014) [35]
N = 20 Non-RCT ACR 1990 Patients Inactive patients N/A IL-8, NA, neutrophils’
function
After 4 months of exercise, there were no
significant changes between exercised and
non-exercised FM patients in the concentration
of serum IL-8Mean age: (n = 10) (n = 10) 3 time points
53 ± 2 years (patients) Pool-aquatic exercise (before, midway
through: 4 months and
After 8 months of exercise, the
concentration of serum IL-8 in exercised
FM patients decreased significantly
compared to the control group (p <0.05).50 ± 4 years
(inactive patients)
8 months at the end of
program: 8 months)
Gender; twice a week (samples were
collected 2 days after
female only (patients) 60 minutes each finishing the last
session of the exercise)
not described
(inactive patients)
serum, plasma
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Table 2 Characteristics of included trials related to cytokines (Continued)
Menzies et al.
(2014) [31]
N = 64 RCT ACR 1990 Guided imagery Usual care N/A IFN-γ, TNF-α,
IL-1β, IL-2, GM-CSF,
There were no statistically significant
differences between the intervention
and control groups in the levels of
pro- and anti-inflammatory cytokines
at baseline, 6 weeks or 10 weeks
Mean age: (n = 30) (n = 34) IL-12, IL-17, IL-8,
MCP-1, MIP-1β, IL-6,
44.5 ± 13.1 years
(guided imagery)
10 weeks 10 weeks IL-7, IL-4, IL-5, IL-10,
IL-13, G-CSF, CRP
49.1 ± 12.4 years
(usual care)
Use CD tracks at
least once a daily
3 time points There was a notable trend in the
increase of plasma IL-7 in the
intervention group, whereas the
control group means remained
relatively constant across the
study interval
Gender: For the first 6 weeks,
listen to the three
(baseline, week 6, week10)
female only CD tracks (each
one CD in two weeks).
plasma
For the last 4 weeks,
listen to the tracks
in any order
ACR American College of Rheumatology, BMI body mass index, CD compact disc, CRP C-reactive protein, CSF cerebrospinal fluid, ESR erythrocyte sedimentation rate, G-CSF granulocyte-colony stimulating factor, GM-CSF
granulocyte macrophage colony-stimulating factor, IFN-γ interferon gamma, IGFBP-3 insulin-like growth factor-binding protein-3, IGF-1 insulin-like growth factor-1, IL interleukin, LPS, lipopolysaccharide, LTB4 leukotriene
B4, MCP-1 monocyte chemoattractant protein-1, MIP-1β macrophage inflammatory protein-1 beta, MMP-3 matrix metallopeptidase-3, N/A not available, NGF nerve growth factor, NPY neuropeptide Y, Non-RCT
non-randomized controlled trial, PGE2 prostaglandin E2, PRL prolactin, RCT randomized controlled trial, RF rheumatoid factor, SP surfactant protein, TNF-α tumor necrosis factor-alpha
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Table 3 Characteristics of included trials related to neuropeptides
Reference Participants Study
design
Diagnosis
of FM
Treatment group Control group Study duration Outcomes Findings
Bojner-Horwitz
et al. (2003) [36]
N = 36 RCT ACR 1990 Dance/movement Waiting control 14 months PRL, NPY, DHEA-S, cortisol The levels of serum PRL in both
groups increased across the study
interval, with the largest increase in
the intervention group
Mean age: (n = 20) (n = 16) 4 time points (at baseline,
and at months 4, 6, and
14 of the study)
57 ± 7.2 years (total) 6 months 6 months There were no significant differences
between baseline and 14 months in
the levels of serum PRL between
the two groups
Gender: once a week
female only 1 h each serum, saliva The levels of serum NPY in both
groups increased from baseline to
month 4, decreased from months
4 − 6, and increased from months
6 − 14
There were no significant differences in
the levels of serum NPY between the
two groups across the study interval
Lund et al.
(2006) [32]
N = 19 RCT ACR 1990 Massage Guided relaxation 10 weeks CRF-LI In the massage group, the
concentrations of urinary CRF-LI
decreased after 6 weeks of massage
treatment (p = 0.01) and 1 month
after completion of treatments (p <0.5)
Mean age: (n = 10) (n = 9) 3 time points (prior to
treatment, after 6-week
treatment and 1 month after
completed treatment) urine
50.7 ± 9.7 years (total) 6 weeks 6 weeks
Gender: twice weekly twice weekly
f+emale only 30 minutes each
(feet and legs
18 minutes, hands
and arm 8 minutes,
face 4 minutes)
30 minutes each
Bjersing et al.
(2012) [26]
N = 49 RCT ACR 1990 Nordic walking Active control:
low-intensity walking
30 weeks SP, NPY, The change in the levels of serum IGF-1
correlated positively with alterations in
CSF SP (p <0.1), NPY (p <0.01) and
pain threshold (p <0.1)Mean age: (N = 26) (n = 23) IL-6, IL-8, IGF-1, IGFBP3,
NGF, MMP-3
52 years (total) 15 weeks 15 weeks 3 time points
Gender: twice a week twice a week (baseline, after 15 weeks
of exercise, 30 weeks
of follow up)female only 40–45 minutes each 40–45 minutes each
serum, CSF
Bazzichi et al.
(2013) [33]
N = 41 RCT ACR 1990 Balneotherapy Active control:
mud-bath therapy
12 weeks BDNF, oxytocin, The concentrations of serum BDNF
significantly decreased in both
balneo-therapy and mud-bath
therapy after 12 weeks (p < 0.05,
p < 0.01, respectively), while there
was no significant change in the
levels of oxytocin.
Mean age: (n = 20) (n = 21) SERT binding
parameters, ATP
54.0 ± 7.2 years
(balneotherapy)
2 weeks 2 weeks 3 time points
6 days a week 6 days a week
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Table 3 Characteristics of included trials related to neuropeptides (Continued)
52.8 ± 10.2 years
(mud-bath therapy)
(at baseline, after 2 weeks
and after 12 weeks)
Gender: 20 minutes each 20 minutes each (mud
pack 10 minutes and
immersion in thermal
water 10 minutes)
19/1 female/male
(balneotherapy)
plasma, serum, salivary
adiponectin, leptin, resistin,
NPY, IGF-1, IGFBP3, NGF
20/1 female/male
(mud-bath therapy)
Bjersing et al.
(2013) [27]
N = 48 RCT ACR 1990 Nordic walking Active control:
low-intensity walking
30 weeks The levels of serum resistin increased
in the group as a whole after 30
weeks (p <0.05) which correlated
with decreased fatigueMean age: (n = 26) (n = 22)
52.0 years (lean group) (lean 4, overweight
15, obese 7)
(lean 5, overweight
11, obese 6)
3 time points The levels of serum NPY increased
in the group as a whole after 30
weeks (p <0.05). This increase
was only significant in obese
patients (p <0.05)
(BMI 18.5 to 24.9,
n = 9)
15 weeks 15 weeks (baseline, after 15 weeks
of exercise, 30 weeks of
follow up) serum, CSF
53.0 years
(overweight group)
twice a week twice a week
(BMI 25 to 29.9, n = 26) 40–45 minutes each 40–45 minutes each
51.0 years (obese
group)
(BMI ≥30, n = 13)
Gender:
female only
ACR American College of Rheumatology, ATP adenosine 5′-triphosphate, BDNF brain-derived neurotrophic factor, BMI body mass index, CRF-L1 corticotropin releasing factor-like immunoreactivity, CSF cerebrospinal
fluid, DHEA-S dehydroepiandrosterone sulfate, IGFBP-3 insulin-like growth factor-binding protein-3, IGF-1, insulin-like growth factor-1, IL interleukin, MMP-3 matrix metallopeptidase-3, NGF nerve growth factor,
Non-RCT non-randomized controlled trial, NPY neuropeptide Y, PRL prolactin, RCT randomized controlled trial, SERT serotonin transporter, SP surfactant protein
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1 month after completed treatments (p <0.5) [32]. For
brain-derived neurotrophic factor (BDNF), Bazzichi et
al. [33] noted that the concentrations of serum BDNF
significantly decreased within each group in both the 2-
week balneotherapy group and the 2-week mud bath
therapy group after 12 weeks (p <0.05, p <0.01, respect-
ively). Furthermore, for resistin, Bjersing et al. [27] dem-
onstrated that the levels of serum resistin in the group
as a whole increased within group after 30 weeks (in-
cluding 15 weeks of exercise and 15 weeks of follow up)
(p <0.05), which correlated with decreased fatigue.
CRP
We included five articles with a total of 223 participants.
All of these articles [28–31, 37] were also included in
the group that utilized cytokines. The characteristics of
each study are shown in Table 4.
Of these studies, Ardiç et al. [37] did not observe
changes in serum CRP levels between pre- and post-
balneotherapy intervention. Three trials [28–30] ob-
served that the levels of serum CRP in the intervention
group decreased within group compared to the baseline
level after 4 months or 8 months of pool-aquatic exer-
cise (p <0.05, each) [28, 29] and 6 months of dietary
therapy [30]. Contrary to these trials, the remaining trial
[31] showed that there were no statistically significant
differences between the guided imagery group and the
group receiving typical care in the levels of plasma CRP
at baseline, 6 weeks or 10 weeks. Comparing the levels
of CRP at baseline, three trials [28, 29, 31] indicated that
the levels of CRP in FM patients were higher than the
reference value.
Discussion
We aimed to assess the effects of non-pharmacological
interventions on biomarkers (specifically cytokines, neu-
ropeptides, and CRP) in patients with FM. Despite the
importance of non-pharmacological interventions in FM
patients, few studies have focused on changes to bio-
markers after non-pharmacological intervention. In fact,
to our knowledge, this is the first systematic review on
this subject. We found only 12 articles that fulfilled our
inclusion criteria. Of these articles, only one trial exam-
ined psychological interventions [31].
Cytokines
Our findings indicated that the levels of serum IL-8 in
FM patients decreased after exercise or multidisciplinary
interventions and those of IL-6 (spontaneous, LPS-
induced, or serum) in FM patients tended to decrease
after exercise or dietary interventions. For IL-8, three tri-
als revealed a reduction in serum IL-8 levels between
pre- and post-intervention, including 3 weeks of multi-
disciplinary exercise or 4 or 8 months of pool-aquatic
exercise [28, 34, 35]. IL-8 is both a pro-inflammatory
cytokine that activates neutrophils and a chemokine that
plays an important role in the infiltration of neutrophils
at inflammation sites [22]. For IL-6, one trial demon-
strated a reduction of the spontaneous and LPS-induced
production of IL-6 between pre-intervention and 8
months post exercise within group [29]. Moreover, an-
other trial showed that the levels of serum IL-6 in the
dietary therapy group decreased between baseline and
after 6 months of intervention within group [30]. Taking
into consideration these findings, exercise, in particular,
could act as an anti-inflammatory influence in FM pa-
tients, although it could act as a pro-inflammatory influ-
ence in healthy individuals [21]. In other words, exercise
interventions could improve the inflammatory status in
FM patients, reaching values close to the basal levels in
the healthy population, by adjusting the inflammatory-
stress feedback mechanism [21].
In terms of anti-inflammatory cytokines, however, our
findings were inconsistent. Ortega et al. [29] reported
that the spontaneous production of IL-10 in FM patients
decreased between pre-intervention and 8 months post
exercise within group, whereas LPS-induced IL-10 to in-
crease within group. It remains unclear if this discrep-
ancy is related to only the diverse functions of IL-10 and
other factors, or the smaller sample size.
In addition, with regard to growth factors, Bjersing et
al. [27] demonstrated that the levels of total serum IGF-
1 in lean FM patients increased after 15 weeks of exer-
cise within group, whereas these levels were unchanged
in overweight or obese FM patients within each group.
They also found evidence of a positive influence of IGF-
1 on fatigue. Given that the fatigue response exercise is
related to levels of body mass index (BMI), changes in
IGF-1 might indicate a beneficial role for fatigue in
obese FM patients.
Neuropeptides and CRP
We found no consistent changes in the levels of neuro-
peptides or CRP due to non-pharmacological interven-
tions. One trial [27] reported that the levels of serum
NPY in obese FM patients significantly increased after
30 weeks (including 15 weeks of exercise and a 15-week
follow-up) (p <0.05) within group, whereas in the other
trial [36] they increased both in the dance/movement
group and the control group compared to baseline after
14 months treatment, within each group.
With respect to other neuropeptides, however, some
notable results have been observed, although only one
trial was conducted to study each neuropeptide. Bjersing
et al. [27] also reported that the levels of serum resistin
in all FM patients increased after 30 weeks (including 15
weeks of exercise and 15-week follow up) within group,
which correlated with decreased fatigue. In view of the
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Table 4 Characteristics of included trials related to CRP
Reference Participants Study design Diagnosis
of FM
Treatment group Control
group
Study
duration
Outcomes Findings
Ardiç et al. (2007)
[37]
N = 31 RCT ACR 1990 Balneotherapy Usual care N/A CRP, IL-1α, PGE2, LTB4, RF, ESR No declaration of the changes
to serum CRP levels between
pre- and post-interventionMean age: (n = 12) (n = 9) 2 time points
43.5 ± 10.2 years
(balneotherapy)
3 weeks 3 weeks (before and at the end of therapy)
48.8 ± 8.8 years
(usual care)
5 days per week Healthy serum
43.4 ± 8.2 years
(healthy)
20 minutes each (n = 10)
Gender:
female only
Ortega et al. (2009)
[28]
N = 27 Non-RCT
(pilot)
ACR Patients Healthy N/A CRP, IL-1β, IL-2, IFN-γ, TNF-α, IL-8, The concentrations of serum CRP
in FM patients were significantly
higher than in the healthy control
group between pre- and
post-exercise (p <0.05)
Age range: (unspecified
year)
(n = 14) (n = 13) IL-6, IL-4, IL-10, NA, cortisol
30–60 years (patients) Pool-aquatic exercise 2 time points After 4 months of exercise,
the level of serum CRP in FM
patients decreased compared
to the baseline level (p <0.05)
28–55 years (healthy) 4 months (before and 2 days after finishing the
exercise)
Gender: 3 days per week
female only 60 minutes each serum
Ortega et al. (2012)
[29]
N = 18 Non-RCT ACR 1990 Patients Healthy N/A CRP, IL-1β, TNF-α, IL-6, IL-10 The concentrations of serum CRP
in FM patients were significantly
higher than in the healthy control
group across the study interval
(p <0.01)
Age range: (n = 9) (n = 9) 3 time points
30–60 years (patients) Pool-aquatic exercise (before, midway through:
4 months and at the end
of program: 8 months)
After 8 months of exercise, the
level of serum CRP in FM patients
decreased compared to the
baseline level (p <0.05)
28–55 years (healthy) 8 months
Gender: twice a week (samples were collected
2 days after finishing the
last session of the
exercise) serum
female only 60 minutes each
Senna et al.
(2012) [30]
N = 83 RCT ACR 1990 Dietary weight loss Usual care N/A CRP, IL-6 The levels of serum CRP in the
intervention group were significantly
lower than the usual care group after
6 months of intervention (p <0.01),
although there were no significant
differences between the two
groups at baseline
Mean age: (N = 41) (n = 42) 2 time points
44.8 ± 13.6 years
(intervention)
6 months 6 months (baseline and after 6 months
of intervention)
(BMI 32.3 ± 1.4) 1200 kcal/day serum
46.3 ± 14.4 years
(usual care)
(with 15–20 % of
energy intake in the
form of protein,
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Table 4 Characteristics of included trials related to CRP (Continued)
50–55 % in the form of
carbo-hydrates, and
approximately 30 % in
the form of fat divided
in three meals)
(BMI 32.8 ± 1.4)
Gender:
male 9.8 %, female
90.2 % (intervention)
male 9.5 %, female
90.5 % (usual care)
Menzies et al. (2014)
[31]
N = 64 RCT ACR 1990 Guided imagery Usual care N/A CRP, IFN-γ, TNF-α, IL-1β, IL-2, GM- There were no statistically significant
differences between the intervention
and control groups in the levels of
plasma CRP at baseline, 6 weeks
or 10 weeks
Mean age: (n = 30) (n = 34) CSF, IL-12, IL-17, IL-8, MCP-1,
MIP-1β,
44.5 ± 13.1 years
(guided imagery)
10 weeks 10 weeks IL-6, IL-7, IL-4, IL-5, IL-10, IL-13,
G-CSF
The levels of plasma CRP for all of
the participants were elevated but
demonstrated little variation from
baseline to 6 weeks or to 10 weeks
(4.27, 4.57, 4.55 mg/L, respectively)
49.1 ± 12.4 years
(Usual care)
use CD tracks at
least once a day
3 time points
Gender: For the first 6 weeks,
listen to the three
(baseline, week 6, week 10) plasma
female only CD tracks (each one
CD in 2 weeks).
For the last 4 weeks,
listen to the tracks
in any order
ACR American College of Rheumatology, BMI body mass index, CD compact disc, CRP C-reactive protein, ESR erythrocyte sedimentation rate, G-CSF granulocyte-colony stimulating factor, GM-CSF granulocyte macrophage
colony-stimulating factor, IFN-γ interferon gamma, IL interleukin, LTB4 leukotriene B4, MCP-1 monocyte chemoattractant protein-1, MIP-1β macrophage inflammatory protein-1 beta, NA noradrenaline, N/A not available,
Non-RCT non-randomized controlled trial, PGE2 prostaglandin E2, RCT randomized controlled trial, RF rheumatoid factor, TNF-α, tumor necrosis factor-alpha
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abovementioned results, they noted that IGF-1 and
resistin were involved in the mechanism that reduced fa-
tigue after moderate exercise in FM patients.
Of the other trials, Lund et al. [32] demonstrated that
the concentrations of urinary CRF-LI in the massage
group decreased after 6 weeks of massage treatment and 1
month after completion of the treatments, within group.
Furthermore, Bazzichi et al. [33] reported that the concen-
trations of serum BDNF significantly decreased in both 2-
week balneotherapy and 2-week mud bath therapy after
12 weeks, within each group. Although these two trials
[32, 33] were not exercise intervention but manipulative
and body-based non-pharmacological interventions, CRF-
L1 and BDNF could be used as indicators of the effects of
each intervention in FM patients.
In terms of CRP, as with the neuropeptides, our find-
ings were inconsistent. In three trials [28–30] the levels
of serum CRP in the intervention group decreased com-
pared to the baseline level after 4 or 8 months of pool-
aquatic exercise (p <0.05, each), within group [28, 29] or
6 months of dietary therapy within group [30]. In contrast,
another trial [31] noted that there were no significant dif-
ferences in the levels of plasma CRP between the guided
imagery group and the group receiving usual care at base-
line, 6 weeks or 10 weeks. Further research comparing
each non-pharmacological intervention, specifically psy-
chological and non-psychological intervention, is required
to clarify the changes in CRP levels in FM patients.
Limitations
The results of this review have several limitations. The
primary limitation is the paucity and low quality of the
included studies. We only included 12 articles (two trials
were conducted with almost the same population), and
of these, there were only 8 RCTs. The quality of the in-
cluded trials has been assessed with the Cochrane risk-
of-bias tool [25], which showed that only two studies
[30, 31] were considered high quality, whereas the others
were low quality with a high risk of bias. With regard to
publication bias, we did not conduct the investigation
using funnel plot analysis due to the high levels of het-
erogeneity among studies, and small sample sizes [38],
and unfortunately we were unable to make any inference
from this.
Another limitation is the high heterogeneity of non-
pharmacological interventions. They consisted of three
types: CAM, exercise, and multidisciplinary therapy. Of
these types of treatment, CAM was also divided into the
following categories: mind-body therapies (e.g., guided im-
agery, dance/movement therapy), manipulative and body-
based therapy (e.g., balneotherapy, massage, mud-bath),
and biological-based therapies (e.g., dietary therapy) [39].
Furthermore, the duration of each intervention and each
study had various patterns. In particular paying attention
to follow up, of our included trials, six [26, 27, 32–34, 36]
were conducted with a follow-up period, although two
[26, 27] were based on almost the same population. Of
these six trials, only two [32, 34] demonstrated that the ef-
fect of each intervention in the levels of biomarkers con-
tinued over the follow-up period within the intervention
group. Lund et al. [32] showed that the concentrations of
urinary CRF-L1 decreased over the 10-week study dur-
ation within the intervention group, and Wang et al. [34]
reported that the levels of serum IL-8 decreased over the
6-month study duration within the intervention group.
On the other hand, although we only included the studies
with non-pharmacological interventions, there are few
studies on the effect of pharmacological treatments in in-
flammatory biomarkers in FM, whereas it appears that an-
tidepressants can normalize levels of some biomarkers
such as ACTH [19]. Our results for each intervention
should be interpreted carefully.
An additional limitation is the high variability of mate-
rials. Biomarkers were investigated in diverse materials:
serum, plasma, cerebrospinal fluid (CSF), urine, and sal-
iva. Thus, a direct comparison of the results is hardly
possible even when the same biomarker was compared.
Moreover, it is unclear whether our findings are ex-
clusive to FM patients [21]. Of all of our included
studies, only FM patients or FM patients and healthy
subjects were included. The non-pharmacological in-
terventions that were conducted in our selected arti-
cles might affect other inflammatory diseases. Ploeger
et al. [40] reported that the inflammatory response in pa-
tients with chronic inflammatory diseases compared to
the healthy population generally increased after acute ex-
ercise. Further research is needed to elucidate whether
non-pharmacological interventions are effective only for
patients with FM.
In addition, there are not enough studies on the effect
of non-pharmacological interventions on inflammatory
biomarkers in healthy individuals, and we are unable to
compare these effects and be certain that the effects re-
ported here are related to FM. For instance, exercise
could act as an anti-inflammatory influence in FM
patients, whereas it could act as a pro-inflammatory
influence in healthy individuals [21]. Further research
is required to explore whether the effects of non-
pharmacological interventions on inflammatory bio-
markers are different in FM patients compared to the
healthy population.
Future directions
Our findings, above all else, highlight the need to con-
duct further RCTs focused on biomarker changes after
non-pharmacological interventions in FM patients. The
following provisions would be helpful to improve future
research in FM patients. First, non-pharmacological
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interventions should include not only exercise but also
psychological treatment. Only one trial, guided imagery
has been conducted as a psychological intervention [31].
Of note, no study has assessed the efficacy of mindful-
ness on biomarkers except for cortisol [41] in FM pa-
tients. We need to elucidate the relationships between
psychological interventions and biomarkers in patients
with FM.
Second, biomarkers should be measured under the same
conditions (e.g., controlling for menstrual phase and med-
ications) to obtain homogeneous patient samples. As
recommended in RCTs, control groups should be ran-
domized and active, using standardized low-intensity non-
pharmacological interventions (and not waiting list or
non-active interventions). Follow up is mandatory and
standardized periods should be accepted by researchers
(for instance: post-treatment, 3-month and 12-month fol-
low up). In addition, more neuropeptides should be in-
cluded as biomarkers. Finally, the relationship between
these biomarkers and pain-related measures deserves to
be studied. Third, participants should be homogeneous,
specifically for disease duration and age. Given that many
of FM patients are female, more attention should be paid
to the effects of menstruation. Moreover, participants who
do not regularly take some kinds of medications (e.g., an-
algesic or psychotropic drugs) would be desirable. Future
trials should be conducted with the aim of reducing the
influence of these medications. On the other hand, par-
ticipants would include not only patients with FM but also
patients with other inflammatory diseases. Few studies have
focused on comparing the effects of non-pharmacological
interventions between FM and other inflammatory
diseases.
Conclusions
In conclusion, our results suggest that the levels of
serum IL-8 in the patients with FM decreased after exer-
cise or multidisciplinary interventions, and IL-6 levels
(spontaneous, LPS-induced, or serum) in FM patients
tended to decrease after exercise or dietary interven-
tions. Exercise intervention, in particular, could act as an
anti-inflammatory influence in FM patients, although it
might act as a pro-inflammatory influence in a healthy
population. To summarize, exercise interventions could
ameliorate the inflammatory status of FM patients, gen-
erating values closer to the baseline levels of healthy in-
dividuals by regulating the inflammatory-stress feedback
mechanism. However, our findings revealed discrepan-
cies in the anti-inflammatory cytokines, but the changes
in IGF-1 might indicate a beneficial role for fatigue in
obese FM patients.
The results for neuropeptides and CRP seem to be in-
consistent. Although only one trial was conducted on
resistin, there was an increase in the levels of serum
resistin in FM patients after an exercise period, which cor-
related with decreased fatigue. IGF-1 and resistin might
be involved in the effects that reduce fatigue in FM pa-
tients. Furthermore, CRF-L1 and BDNF could be used as
indicators of efficacy related to non-pharmacological
interventions in FM patients.
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